Adamax
Nootropic Research Peptide
Size: 5mg


With code FALL
Stacks with code FALL
Adamax is an enhanced derivative of the nootropic Semax — an N-acetylated, adamantane-modified ACTH(4-10) analog studied for neuroprotective and cognitive-signaling research.
Adamax (Modified Semax)
Enhanced derivative of the ACTH(4-10) analog Semax (MEHFPGP)
Carries N-terminal acetylation plus an adamantane modification
Modifications studied for greater stability and blood-brain-barrier penetration
Investigated for BDNF / TrkB-related signaling like its Semax parent
Referenced in nootropic and neuroprotection research models
Research Use Notes
Supplied as lyophilized powder
Requires reconstitution before use
Research Water required for mixing (sold separately)
Swirl gently, never shake
Storage
Store lyophilized vial frozen for long-term holding
Keep reconstituted solution at 2 to 8°C
Protect from light and heat
Handling
Maintain sterile workflow during reconstitution
For laboratory research use only
Certificate of Analysis
Independently 8x Tested by Kovera Labs and/or ILS Labs
(Click here to learn about 8x testing)
All certificates are issued by independent ISO-accredited laboratories. Lot-specific documents are made available to qualified research professionals on request.
Frequently Bought Together
Commonly paired to support consistent, reliable experimentation.
Compound Information
Technical specifications
What Is Adamax?
Modified Semax · N-acetyl, adamantane-modified ACTH (4-10) analog
- Type
- Synthetic peptide (Semax derivative)
- Class
- Nootropic / ACTH (4-10) analog
- Parent
- Semax (MEHFPGP)
- Modification
- N-acetyl + adamantane
Stability Information
-20°C
24+ months
2-8°C
~30 days
Sources & References
Peer-reviewed research
Products are intended solely for laboratory and scientific research purposes. Not intended for human consumption, veterinary use, diagnosis, treatment, cure, or prevention of disease.


All the research compounds you need, with the confidence that every batch is 8× tested before it ships.
Subscribe to our Newsletter
Subscribe to our newsletter to get daily insights, news, updates.
















